{"id":745541,"date":"2017-06-03T07:00:00","date_gmt":"2017-06-03T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to\/"},"modified":"2025-11-07T01:26:29","modified_gmt":"2025-11-07T06:26:29","slug":"longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to\/","title":{"rendered":"Longer Term Follow-Up Data with Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be Presented at 2017 ASCO Annual Meeting"},"content":{"rendered":"<p class=\"bwalignc\">       Data Include Overall Response Rate, Progression-Free Survival and        Overall Survival Findings from Additional Five Months of Follow-Up in        KEYNOTE-021     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced updated results from KEYNOTE-021, Cohort G1, which<br \/>\n      studied KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the company\u2019s anti-PD-1<br \/>\n      therapy, in combination with pemetrexed and carboplatin (pem\/carbo) in<br \/>\n      the first-line treatment of patients with advanced nonsquamous non-small<br \/>\n      cell lung cancer (NSCLC), irrespective of PD-L1 expression. Data \u2013 which<br \/>\n      are based on an additional five months of follow-up \u2013 demonstrated<br \/>\n      continued benefit with KEYTRUDA plus pem\/carbo, including an overall<br \/>\n      response rate (ORR) of 56.7 percent compared to 30.2 percent with<br \/>\n      pem\/carbo alone (95% CI, 8.9%-42.3%; P = 0.0016). Progression-free<br \/>\n      survival (PFS) was longer in the KEYTRUDA combination group, with the<br \/>\n      median not reached (95% CI, 8.5 months-not reached) compared to 8.9<br \/>\n      months in the pem\/carbo group (95% CI, 6.2-10.3) (HR 0.50 [95% CI,<br \/>\n      0.29-0.84, P = 0.0038]). Though statistical significance was not met, an<br \/>\n      updated overall survival (OS) analysis for the combination with KEYTRUDA<br \/>\n      plus pem\/carbo showed a trend towards improvement compared to patients<br \/>\n      treated with pem\/carbo alone (HR, 0.69 [95% CI, 0.36-1.31, P = 0.13]).<br \/>\n      The findings are being presented at the 2017 American Society of<br \/>\n      Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract #9094).\n    <\/p>\n<p>\n      \u201cWith an additional five months of follow-up, we are seeing continued<br \/>\n      benefits in overall response rate and progression-free survival with<br \/>\n      KEYTRUDA plus pemetrexed\/carboplatin,\u201d said Dr. Vassiliki<br \/>\n      Papadimitrakopoulou, section chief thoracic medical oncology, UT MD<br \/>\n      Anderson Cancer Center. \u201cThese data support the use of this combination<br \/>\n      regimen for patients with nonsquamous metastatic non-small cell lung<br \/>\n      cancer, irrespective of PD-L1 expression.\u201d\n    <\/p>\n<p>\n      Merck has one of the world\u2019s most robust clinical development programs<br \/>\n      in immuno-oncology. The program includes extensive research in lung<br \/>\n      cancer with multiple registration-enabling studies for KEYTRUDA<br \/>\n      (pembrolizumab) currently underway. The KEYTRUDA clinical development<br \/>\n      program encompasses more than 30 tumor types in more than 500 clinical<br \/>\n      trials, including more than 300 trials that combine KEYTRUDA with other<br \/>\n      cancer treatments.\n    <\/p>\n<p>\n      \u201cA significant unmet need in lung cancer has existed for decades, and we<br \/>\n      are now seeing that KEYTRUDA combined with pemetrexed and carboplatin<br \/>\n      shows a continued benefit for patients with metastatic nonsquamous<br \/>\n      non-small cell lung cancer in the first-line treatment of this disease,\u201d<br \/>\n      said Dr. Roger Dansey, senior vice president and therapeutic area head,<br \/>\n      oncology late-stage development, Merck Research Laboratories.&nbsp;\u201cWe are<br \/>\n      encouraged by these additional data and look forward to continuing to<br \/>\n      study this combination through our ongoing clinical research program.\u201d\n    <\/p>\n<p>\n      <b>KEYNOTE-021, Cohort G1: Data in First-Line Patients Irrespective of<br \/>\n      PD-L1 Expression (Abstract #9094)<\/b>\n    <\/p>\n<p>\n      Cohort G1 of the multicenter, open-label, phase 1\/2 multi-cohort<br \/>\n      KEYNOTE-021 study evaluated the efficacy and safety of KEYTRUDA in<br \/>\n      combination with pemetrexed and carboplatin (KEYTRUDA + pem\/carbo<br \/>\n      combination group) compared with pemetrexed and carboplatin (pem\/carbo<br \/>\n      group) in 123 patients with metastatic, nonsquamous, EGFR- and<br \/>\n      ALK-negative NSCLC in the first-line treatment setting. The<br \/>\n      KEYNOTE-021G1 trial was conducted in collaboration with&nbsp;Eli Lilly and<br \/>\n      Company, the maker of pemetrexed. Patients were randomized to receive<br \/>\n      KEYTRUDA + pem\/carbo (n=60) or pem\/carbo alone (n=63). Patients in the<br \/>\n      KEYTRUDA + pem\/carbo combination group received KEYTRUDA (200 mg),<br \/>\n      pemetrexed (500 mg\/m<sup>2<\/sup>) and carboplatin (AUC 5 mg\/mL\/min)<br \/>\n      every three weeks for four cycles followed by KEYTRUDA every three<br \/>\n      weeks. In the pem\/carbo group, patients received pemetrexed (500 mg\/m<sup>2<\/sup>)<br \/>\n      and carboplatin (AUC 5 mg\/mL\/min) alone for four cycles. At the<br \/>\n      investigator\u2019s discretion, maintenance pemetrexed (500 mg\/m<sup>2<\/sup>)<br \/>\n      every three weeks was permitted in both treatment groups. The major<br \/>\n      efficacy outcome measure was overall response rate (ORR) as assessed by<br \/>\n      blinded independent central review (BICR) using Response Evaluation<br \/>\n      Criteria in Solid Tumors (RECIST) version 1.1. Additional efficacy<br \/>\n      outcome measures were PFS as assessed by BICR using RECIST 1.1, duration<br \/>\n      of response and OS.\n    <\/p>\n<p>\n      Data to be presented at ASCO include a median follow-up of 14.5 months<br \/>\n      (range: 0.8-24.0). In this analysis, the KEYTRUDA + pem\/carbo<br \/>\n      combination demonstrated improvement over pem\/carbo alone in response<br \/>\n      rate, duration of response and PFS. ORR was 56.7 percent in the KEYTRUDA<br \/>\n      + pem\/carbo combination group compared to 30.2 percent in the pem\/carbo<br \/>\n      group (95% CI, 8.9%-42.3%; P = 0.0016). The median duration of response<br \/>\n      had not been reached in the KEYTRUDA + pem\/carbo combination group<br \/>\n      (range: 1.4+ to 18.6+) and was 16.2 months (range: 2.8 to 20.7+) in the<br \/>\n      pem\/carbo group.\n    <\/p>\n<p>\n      Findings also included an analysis based on PD-L1 expression. In<br \/>\n      patients whose tumors did not express PD-L1 (TPS of less than 1%), ORR<br \/>\n      was 62 percent (95% CI, 38-82) with KEYTRUDA (pembrolizumab) + pem\/carbo<br \/>\n      compared to 13 percent (95% CI, 3-34) with pem\/carbo alone. In patients<br \/>\n      whose tumors expressed PD-L1 (TPS of 1% or more), ORR was 54 percent<br \/>\n      (95% CI, 37-70) with KEYTRUDA+ pem\/carbo compared to 40 percent (95% CI,<br \/>\n      25-57) with pem\/carbo alone. Among these patients, those with high<br \/>\n      levels of PD-L1 (TPS of 50% or more) were most likely to respond, with<br \/>\n      an ORR of 80 percent (95% CI, 56-94) with KEYTRUDA + pem\/carbo compared<br \/>\n      to 41 percent (95% CI, 18-67) with pem\/carbo alone. In patients with<br \/>\n      lower levels of PD-L1 expression (TPS of one to 49%), ORR was 26 percent<br \/>\n      (95% CI, 9-51) with KEYTRUDA + pem\/carbo compared to 39 percent (95% CI,<br \/>\n      20-61) with pem\/carbo alone.\n    <\/p>\n<p>\n      PFS was longer in the KEYTRUDA combination group, with the median not<br \/>\n      reached (95% CI, 8.5 months-not reached) compared to 8.9 months in the<br \/>\n      pem\/carbo group (95% CI, 6.2-10.3) (HR 0.50 [95% CI, 0.29-0.84, P =<br \/>\n      0.0038]). At nine and 12 months, PFS was 63.2 percent and 56.4 percent,<br \/>\n      respectively, in the KEYTRUDA + pem\/carbo combination group compared to<br \/>\n      48.1 percent and 33.9 percent in the pem\/carbo group.\n    <\/p>\n<p>\n      Seventy-five percent (n=36\/48) of patients in the pem\/carbo group<br \/>\n      received subsequent anti-PD-1 or PD-L1 therapy, including 22 who<br \/>\n      received KEYTRUDA as part of study crossover.\n    <\/p>\n<p>\n      Though statistical significance was not met in an analysis of OS, the<br \/>\n      KEYTRUDA + pem\/carbo combination was associated with a 31 percent (HR,<br \/>\n      0.69 [95% CI, 0.36-1.31, P = 0.13]) reduction in the risk of death.<br \/>\n      Median OS was not reached in either group; at nine and 12 months, the<br \/>\n      estimated OS rate was 84.6 percent and 76.0 percent, respectively, in<br \/>\n      the KEYTRUDA + pem\/carbo combination group compared to 82.3 percent and<br \/>\n      69.3 percent in the pem\/carbo group.\n    <\/p>\n<p>\n      The safety findings were consistent with what has been seen in previous<br \/>\n      trials among patients treated with KEYTRUDA. Grade 3-5 treatment-related<br \/>\n      adverse events occurring in the KEYTRUDA + pem\/carbo group were anemia<br \/>\n      (11.9%), neutrophil count decreased (6.8%), fatigue (3.4%), nausea<br \/>\n      (1.7%), rash (1.7%), vomiting (1.7%), aspartate aminotransferase<br \/>\n      increased (1.7%) and alanine aminotransferase increased (1.7%). The most<br \/>\n      common immune-mediated adverse events of any grade in patients receiving<br \/>\n      KEYTRUDA + pem\/carbo were hypothyroidism (11.9%), hyperthyroidism<br \/>\n      (8.5%), pneumonitis (6.8%), infusion reactions (3.4%), severe skin<br \/>\n      toxicity (1.7%) and colitis (1.7%). There was one treatment-related<br \/>\n      death in a patient receiving KEYTRUDA + pem\/carbo and two in patients<br \/>\n      receiving pem\/carbo alone.\n    <\/p>\n<p>\n      <b>About Lung Cancer<\/b>\n    <\/p>\n<p>\n      Lung cancer, which forms in the tissues of the lungs, usually within<br \/>\n      cells lining the air passages, is the leading cause of cancer death<br \/>\n      worldwide. Each year, more people die of lung cancer than die of colon,<br \/>\n      breast and prostate cancers combined. The two main types of lung cancer<br \/>\n      are non-small cell and small cell. NSCLC is the most common type of lung<br \/>\n      cancer, accounting for about 85 percent of all cases. The five-year<br \/>\n      survival rate for patients suffering from highly advanced, metastatic<br \/>\n      (Stage IV) lung cancers is estimated to be two percent.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Studies of KEYTRUDA \u2013 from the largest immuno-oncology program in the<br \/>\n      industry with more than 500 trials \u2013 include a wide variety of cancers<br \/>\n      and treatment settings. The KEYTRUDA clinical program seeks to<br \/>\n      understand factors that predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including the exploration of several<br \/>\n      different biomarkers across a broad range of tumors.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single-dose vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab)<\/b> <b>Indications<br \/>\n      and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [tumor proportion score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA<br \/>\n      (pembrolizumab).\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with<br \/>\n      locally advanced or metastatic urothelial carcinoma who are not eligible<br \/>\n      for cisplatin-containing chemotherapy. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who have disease progression<br \/>\n      during or following platinum-containing chemotherapy or within 12 months<br \/>\n      of neoadjuvant or adjuvant treatment with platinum-containing<br \/>\n      chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      pediatric patients with MSI-H cancer, KEYTRUDA is administered at a dose<br \/>\n      of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) can cause immune-mediated pneumonitis,<br \/>\n      including fatal cases. Pneumonitis occurred in 94 (3.4%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 1 (0.8%), 2 (1.3%), 3<br \/>\n      (0.9%), 4 (0.3%), and 5 (0.1%) pneumonitis, and occurred more frequently<br \/>\n      in patients with a history of prior thoracic radiation (6.9%) compared<br \/>\n      to those without (2.9%). Monitor patients for signs and symptoms of<br \/>\n      pneumonitis. Evaluate suspected pneumonitis with radiographic imaging.<br \/>\n      Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold<br \/>\n      KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. Thyroiditis occurred in 16 (0.6%) of 2799 patients<br \/>\n      receiving KEYTRUDA, including Grade 2 (0.3%) thyroiditis. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) can cause immune-mediated nephritis. Nephritis<br \/>\n      occurred in 9 (0.3%) of 2799 patients receiving KEYTRUDA, including<br \/>\n      Grade 2 (0.1%), 3 (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for<br \/>\n      changes in renal function. Administer corticosteroids for Grade 2 or<br \/>\n      greater nephritis. Withhold KEYTRUDA for Grade 2; permanently<br \/>\n      discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. These immune-mediated reactions may occur in any organ<br \/>\n      system. For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), exfoliative dermatitis, bullous pemphigoid, rash<br \/>\n      (1.4%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis,<br \/>\n      vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising<br \/>\n      in a patient with inflammatory foci in brain parenchyma. In addition,<br \/>\n      myelitis and myocarditis were reported in other clinical trials,<br \/>\n      including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA. Treatment with KEYTRUDA may increase the risk of rejection<br \/>\n      in solid organ transplant recipients. Consider the benefit of treatment<br \/>\n      with KEYTRUDA vs the risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA. Of 23 patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after treatment with KEYTRUDA<br \/>\n      on any trial, 6 patients (26%) developed graft-versus-host-disease<br \/>\n      (GVHD), one of which was fatal, and 2 patients (9%) developed severe<br \/>\n      hepatic veno-occlusive disease (VOD) after reduced-intensity<br \/>\n      conditioning, one of which was fatal. Cases of fatal hyperacute GVHD<br \/>\n      after allogeneic HSCT have also been reported in patients with lymphoma<br \/>\n      who received a PD-1 receptor\u2013blocking antibody before transplantation.<br \/>\n      These complications may occur despite intervening therapy between PD-1<br \/>\n      blockade and allogeneic HSCT. Follow patients closely for early evidence<br \/>\n      of transplant-related complications such as hyperacute GVHD, severe<br \/>\n      (Grade 3 to 4) acute GVHD, steroid-requiring febrile syndrome, hepatic<br \/>\n      VOD, and other immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA (pembrolizumab) can cause<br \/>\n      fetal harm when administered to a pregnant woman. If used during<br \/>\n      pregnancy, or if the patient becomes pregnant during treatment, apprise<br \/>\n      the patient of the potential hazard to a fetus. Advise females of<br \/>\n      reproductive potential to use highly effective contraception during<br \/>\n      treatment and for 4 months after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      When KEYTRUDA was administered in combination with carboplatin and<br \/>\n      pemetrexed (carbo\/pem), KEYTRUDA was discontinued in 10% of 59 patients.<br \/>\n      The most common adverse reaction resulting in discontinuation of<br \/>\n      KEYTRUDA (\u22652%) was acute kidney injury (3.4%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 39% of patients; the most common<br \/>\n      (\u22652%) were fatigue (8%), neutrophil count decreased (8%), anemia (5%),<br \/>\n      dyspnea (3.4%), and pneumonitis (3.4%). The most common adverse<br \/>\n      reactions (\u226520%) with KEYTRUDA compared to carbo\/pem alone were fatigue<br \/>\n      (71% vs 50%), nausea (68% vs 56%), constipation (51% vs 37%), rash (42%<br \/>\n      vs 21%), vomiting (39% vs 27%), dyspnea (39% vs 21%), diarrhea (37% vs<br \/>\n      23%), decreased appetite (31% vs 23%), headache (31% vs 16%), cough (24%<br \/>\n      vs 18%), dizziness (24% vs 16%), insomnia (24% vs 15%), pruritus (24% vs<br \/>\n      4.8%), peripheral edema (22% vs 18%), dysgeusia (20% vs 11%), alopecia<br \/>\n      (20% vs 3.2%), upper respiratory tract infection (20% vs 3.2%), and<br \/>\n      arthralgia (15% vs 24%). This study was not designed to demonstrate a<br \/>\n      statistically significant difference in adverse reaction rates for<br \/>\n      KEYTRUDA as compared to carbo\/pem alone for any specified adverse<br \/>\n      reaction.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 500 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51569351&amp;newsitemid=20170603005020&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=93d644f93e039b548ad9418b5e355194\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51569351&amp;newsitemid=20170603005020&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=222c8994890d765139a7d9bf7523e07a\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51569351&amp;newsitemid=20170603005020&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=f5eb8c2c656ee71055970a407151d2f2\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51569351&amp;newsitemid=20170603005020&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=5943e859a4ae4dcbf8e281cda56858ad\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51569351&amp;newsitemid=20170603005020&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=e592c1aa8daa566c7edac7ca6c0a9082\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51569351&amp;newsitemid=20170603005020&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=2e5e2d8352fa13a1f2c136e9cf8091ae\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51569351&amp;newsitemid=20170603005020&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=4083f41294a08f51b2b137bab7d98896\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51569351&amp;newsitemid=20170603005020&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=eec92f4505e289d001e0e6dc3186d5fe\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51569351&amp;newsitemid=20170603005020&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=9&amp;md5=00a4b91127b523f6af78add4a2ef1909\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51569351&amp;newsitemid=20170603005020&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=10&amp;md5=fc688dbb556010325b5a6788b2757808\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170603005020r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Teresa        Mueller, 908-740-1884<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Data Include Overall Response Rate, Progression-Free Survival and Overall Survival Findings from Additional Five Months of Follow-Up in KEYNOTE-021 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated results from KEYNOTE-021, Cohort G1, which studied KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in combination with pemetrexed and carboplatin (pem\/carbo) in the first-line treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. Data \u2013 which are based on an additional five months of follow-up \u2013 demonstrated continued benefit with KEYTRUDA plus pem\/carbo, including an overall response rate (ORR) of 56.7 percent compared to 30.2 percent with pem\/carbo alone (95% CI, 8.9%-42.3%; P = 0.0016). Progression-free survival (PFS) was longer in the KEYTRUDA combination group, with the median not reached (95% CI, 8.5 months-not reached) compared to 8.9 months in the pem\/carbo group<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[149,53,64,55,289],"class_list":["post-745541","news_item","type-news_item","status-publish","hentry","tag-asco","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Longer Term Follow-Up Data with Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be Presented at 2017 ASCO Annual Meeting - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Longer Term Follow-Up Data with Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be Presented at 2017 ASCO Annual Meeting - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Data Include Overall Response Rate, Progression-Free Survival and Overall Survival Findings from Additional Five Months of Follow-Up in KEYNOTE-021 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated results from KEYNOTE-021, Cohort G1, which studied KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in combination with pemetrexed and carboplatin (pem\/carbo) in the first-line treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. Data \u2013 which are based on an additional five months of follow-up \u2013 demonstrated continued benefit with KEYTRUDA plus pem\/carbo, including an overall response rate (ORR) of 56.7 percent compared to 30.2 percent with pem\/carbo alone (95% CI, 8.9%-42.3%; P = 0.0016). Progression-free survival (PFS) was longer in the KEYTRUDA combination group, with the median not reached (95% CI, 8.5 months-not reached) compared to 8.9 months in the pem\/carbo group\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"19 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to\\\/\",\"name\":\"Longer Term Follow-Up Data with Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be Presented at 2017 ASCO Annual Meeting - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-06-03T07:00:00+00:00\",\"dateModified\":\"2025-11-07T06:26:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Longer Term Follow-Up Data with Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be Presented at 2017 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Longer Term Follow-Up Data with Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be Presented at 2017 ASCO Annual Meeting - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to\/","og_locale":"en_US","og_type":"article","og_title":"Longer Term Follow-Up Data with Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be Presented at 2017 ASCO Annual Meeting - Merck.com","og_description":"Data Include Overall Response Rate, Progression-Free Survival and Overall Survival Findings from Additional Five Months of Follow-Up in KEYNOTE-021 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated results from KEYNOTE-021, Cohort G1, which studied KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in combination with pemetrexed and carboplatin (pem\/carbo) in the first-line treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. Data \u2013 which are based on an additional five months of follow-up \u2013 demonstrated continued benefit with KEYTRUDA plus pem\/carbo, including an overall response rate (ORR) of 56.7 percent compared to 30.2 percent with pem\/carbo alone (95% CI, 8.9%-42.3%; P = 0.0016). Progression-free survival (PFS) was longer in the KEYTRUDA combination group, with the median not reached (95% CI, 8.5 months-not reached) compared to 8.9 months in the pem\/carbo group","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:29+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"19 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to\/","name":"Longer Term Follow-Up Data with Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be Presented at 2017 ASCO Annual Meeting - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-06-03T07:00:00+00:00","dateModified":"2025-11-07T06:26:29+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/longer-term-follow-up-data-with-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-in-first-line-nonsquamous-metastatic-non-small-cell-lung-cancer-nsclc-to\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Longer Term Follow-Up Data with Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be Presented at 2017 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"71029b67-4011-4b1f-938c-de8a11b2be69","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Longer-Term-Follow-Up-Data-with-Mercks-KEYTRUDA-pembrolizumab-in-Combination-with-Pemetrexed-and-Carboplatin-in-First-Line-Nonsquamou-X2BY0.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":2,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745541\/revisions"}],"predecessor-version":[{"id":3674899,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745541\/revisions\/3674899"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745541"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}